These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. (D)-2-tert-Butoxycarbonylamino-5,5-difluoro-5-phenyl-pentanoic acid: synthesis and incorporation into the growth hormone secretagogues. Li J; Chen SY; Murphy BJ; Flynn N; Seethala R; Slusarchyk D; Yan M; Sleph P; Zhang H; Humphreys WG; Ewing WR; Robl JA; Gordon D; Tino JA Bioorg Med Chem Lett; 2008 Jul; 18(14):4072-4. PubMed ID: 18554903 [TBL] [Abstract][Full Text] [Related]
4. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Patchett AA; Nargund RP; Tata JR; Chen MH; Barakat KJ; Johnston DB; Cheng K; Chan WW; Butler B; Hickey G Proc Natl Acad Sci U S A; 1995 Jul; 92(15):7001-5. PubMed ID: 7624358 [TBL] [Abstract][Full Text] [Related]
5. Chronic central infusion of growth hormone secretagogues: effects on fos expression and peptide gene expression in the rat arcuate nucleus. Bailey AR; Giles M; Brown CH; Bull PM; Macdonald LP; Smith LC; Smith RG; Leng G; Dickson SL Neuroendocrinology; 1999 Aug; 70(2):83-92. PubMed ID: 10461022 [TBL] [Abstract][Full Text] [Related]
6. Potent 3-spiropiperidine growth hormone secretagogues. Yang L; Morriello G; Prendergast K; Cheng K; Jacks T; Chan WW; Schleim KD; Smith RG; Patchett AA Bioorg Med Chem Lett; 1998 Jan; 8(1):107-12. PubMed ID: 9925440 [TBL] [Abstract][Full Text] [Related]
7. New growth hormone secretagogues: C-terminal modified sulfonamide-analogues of NN703. Peschke B; Hansen BS Bioorg Med Chem Lett; 1999 May; 9(9):1295-8. PubMed ID: 10340617 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological activities of phenyl piperazine-based peptidomimetic growth hormone secretagogues. Barakat KJ; Cheng K; Chan WW; Butler BS; Jacks TM; Schleim KD; Hora DF; Hickey GJ; Smith RG; Patchett AA; Nargund RP Bioorg Med Chem Lett; 1998 Jun; 8(11):1431-6. PubMed ID: 9871779 [TBL] [Abstract][Full Text] [Related]
10. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Lee J; Kwon A; Chae HW; Lee WJ; Kim TH; Kim HS Yonsei Med J; 2018 Dec; 59(10):1174-1180. PubMed ID: 30450851 [TBL] [Abstract][Full Text] [Related]
11. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Jacks T; Smith R; Judith F; Schleim K; Frazier E; Chen H; Krupa D; Hora D; Nargund R; Patchett A; Hickey G Endocrinology; 1996 Dec; 137(12):5284-9. PubMed ID: 8940347 [TBL] [Abstract][Full Text] [Related]
12. The discovery of highly potent CGRP receptor antagonists. Stump CA; Bell IM; Bednar RA; Bruno JG; Fay JF; Gallicchio SN; Johnston VK; Moore EL; Mosser SD; Quigley AG; Salvatore CA; Theberge CR; Blair Zartman C; Zhang XF; Kane SA; Graham SL; Vacca JP; Williams TM Bioorg Med Chem Lett; 2009 Jan; 19(1):214-7. PubMed ID: 19010673 [TBL] [Abstract][Full Text] [Related]
13. Thiazole-derived potent, highly bioavailable short duration growth hormone secretagogues. Yang L; Morriello G; Leung K; Jacks T; Cheng K; Schleim KD; Smith R; Patchett AA Bioorg Med Chem Lett; 1999 Jul; 9(13):1761-6. PubMed ID: 10406638 [TBL] [Abstract][Full Text] [Related]
14. Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. Hansen TK; Ankersen M; Raun K; Hansen BS Bioorg Med Chem Lett; 2001 Jul; 11(14):1915-8. PubMed ID: 11459660 [TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of the oxindole growth hormone secretagogues. Tokunaga T; Hume WE; Nagamine J; Kawamura T; Taiji M; Nagata R Bioorg Med Chem Lett; 2005 Apr; 15(7):1789-92. PubMed ID: 15780607 [TBL] [Abstract][Full Text] [Related]
16. Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. Frascarelli S; Ghelardoni S; Ronca-Testoni S; Zucchi R Basic Res Cardiol; 2003 Nov; 98(6):401-5. PubMed ID: 14556085 [TBL] [Abstract][Full Text] [Related]
17. Spirocyclopropane compounds II. Synthesis and biological activities of spiro[cyclopropane-1,2-[2H]indo]-3'(1'H)-ones. Kawada M; Sugihara H; Mikami I; Kawai K; Kuzuna S; Noguchi S; Sanno Y Chem Pharm Bull (Tokyo); 1981 Jul; 29(7):1912-9. PubMed ID: 6975665 [No Abstract] [Full Text] [Related]
18. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249 [TBL] [Abstract][Full Text] [Related]
19. Functionalized spirooxindole-indolizine hybrids: Stereoselective green synthesis and evaluation of anti-inflammatory effect involving TNF-α and nitrite inhibition. Kumar RS; Antonisamy P; Almansour AI; Arumugam N; Periyasami G; Altaf M; Kim HR; Kwon KB Eur J Med Chem; 2018 May; 152():417-423. PubMed ID: 29751235 [TBL] [Abstract][Full Text] [Related]